Biochemical overviews underscore that IGFBP-6 is uniquely IGF-II-preferring among IGFBPs, so any post-translational modification that weakens IGF-II affinity would be expected to have disproportionate consequences for IGF signaling in liver disease [65]. Here, IGFBP6 is linked to liver disorder.